Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Bolcaen, Julie![]() |
|
dc.contributor.author | Kleynhans, Janke![]() |
|
dc.contributor.author | Nair, Shankari![]() |
|
dc.contributor.author | Verhoeven, Jeroen![]() |
|
dc.contributor.author | Goethals, Ingeborg![]() |
|
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.contributor.author | Vandevoorde, Charlot![]() |
|
dc.contributor.author | Ebenhan, Thomas![]() |
|
dc.date.accessioned | 2022-09-21T05:04:47Z | |
dc.date.available | 2022-09-21T05:04:47Z | |
dc.date.issued | 2021-07-06 | |
dc.description.abstract | Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of care. However, the future promises efficient patient-tailored treatments, including targeted radionuclide therapy (TRT). Advances in radiopharmaceutical development have unlocked the possibility to assess disease at the molecular level allowing individual diagnosis. This leads to the possibility of choosing a tailored, targeted approach for therapeutic modalities. Therapeutic modalities based on radiopharmaceuticals are an exciting development with great potential to promote a personalised approach to medicine. However, an effective targeted radionuclide therapy (TRT) for the treatment of GB entails caveats and requisites. This review provides an overview of existing nuclear imaging and TRT strategies for GB. A critical discussion of the optimal characteristics for new GB targeting therapeutic radiopharmaceuticals and clinical indications are provided. Considerations for target selection are discussed, i.e. specific presence of the target, expression level and pharmacological access to the target, with particular attention to blood-brain barrier crossing. An overview of the most promising radionuclides is given along with a validation of the relevant radiopharmaceuticals and theranostic agents (based on small molecules, peptides and monoclonal antibodies). Moreover, toxicity issues and safety pharmacology aspects will be presented, both in general and for the brain in particular. | en_US |
dc.description.department | Nuclear Medicine | en_US |
dc.description.librarian | dm2022 | en_US |
dc.description.uri | http://www.thno.org | en_US |
dc.identifier.citation | Bolcaen, J., Kleynhans, J., Nair, S., Verhoeven, J., Goethals, I., Sathekge, M., Vandevoorde, C. & Ebenhan, T. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. Theranostics. 2021 Jul 6;11(16):7911-7947. doi: 10.7150/thno.56639. | en_US |
dc.identifier.issn | 1838-7640 (online) | |
dc.identifier.other | 10.7150/thno.56639 | |
dc.identifier.uri | https://repository.up.ac.za/handle/2263/87236 | |
dc.language.iso | en | en_US |
dc.publisher | Ivyspring International Publisher | en_US |
dc.rights | © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License. | en_US |
dc.subject | Radiochemistry | en_US |
dc.subject | Gioblastoma | en_US |
dc.subject | Theranostics | en_US |
dc.subject | PET SPECT imaging | en_US |
dc.subject | Targeted radionuclide therapy (TRT) | en_US |
dc.subject | Single photon emission computed tomography (SPECT) | en_US |
dc.subject | Positron emission tomography (PET) | en_US |
dc.title | A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma | en_US |
dc.type | Article | en_US |